This channel includes news on cardiovascular care delivery, including how patients are diagnosed and treated, cardiac care guidelines, policies or legislation impacting patient care, device recalls that may impact patient care, and cardiology practice management.
Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.
It’s been years since AI proponents started promising big returns on healthcare providers’ investments in the technology. The results have yet to catch up with the pitches. What’s the holdup?
SCAI celebrated cardiologists William W. O'Neill, MD, and Cindy L. Grines, MD, for the important roles they played in the development of primary PCI. “It was challenging,” Grines explained. “We had the pharmaceutical industry that was anti-primary angioplasty and we had a lot of our own colleagues that were anti-primary angioplasty."
Self-expanding and balloon-expandable TAVR valves are associated with comparable success rates and one-year outcomes when treating type 1 bicuspid aortic stenosis. However, each valve type comes with its own advantages and disadvantages.
Asian patients are rarely represented in large TAVR trials, the authors wrote, so they focused on nearly 1,200 patients from South Korea to provide a fresh perspective.
More than two-thirds of hospital executives, 70%, say their institution has a formal or comprehensive strategy in place for selecting, acquiring and integrating digital health products.
Abbott's HeartMate 3 LVAD is the only FDA-approved device of its kind currently available in the United States. Should reports of adverse events worry cardiologists? Or are they to be expected when treating such a vulnerable patient population?
While GLP-1 drugs were originally developed to treat diabetes, researchers keep finding additional ways these medications can potentially benefit patients.